---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-008336"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2022-06-14T23:59:59+00:00"
generated_at: "2026-06-25T01:53:42.862276+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q2 FY2022 revenue $5.0M, net income $0.2M; stable YoY

## Summary
- Revenue for Q2 ended April 30, 2022 was ~$5.0M, up ~$0.1M from prior-year quarter.
- Net income for Q2 was ~$0.2M, reflecting no significant change YoY.
- Six-month revenue ~$10.0M, net income ~$0.5M, both essentially flat YoY.
- CEO cites steady execution and focus on client services amid global uncertainties.

## SEC filing metadata
- accession: 0001654954-22-008336
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2022-06-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495422008336/0001654954-22-008336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495422008336/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-008336
- JSON: https://secwatch.observer/filing/0001654954-22-008336.json
- Plain text: https://secwatch.observer/filing/0001654954-22-008336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.